Phase I dose escalation trial of a 100 aa synthetic mucin peptide admixed with SB-AS2 as adjuvant in locally advanced and resected pancreatic cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2016 Biomarkers information updated
- 10 Sep 2005 New trial record.